Gilead Sciences

Traded on the St. Petersburg Stock Exchange
Gilead Sciences is an American biopharmaceutical company that researches, develops and commercializes drugs. The company focuses primarily on antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi. It is also engaged in drug development research aimed at treating cancer. The company was founded in 1987.
Gilead Sciences stock price chart
-10%
P/E adj.
Net profit (adj.)
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Gilead Sciences balance sheet

Report period2018 2019 2020 2021 2022 2023
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Gilead Sciences cash flows

Report period2018 2019 2020 2021 2022 2023
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
Adjusted Earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS
Adjusted EPS

Gilead Sciences multipliers

Report period2018 2019 2020 2021 2022 2023
P/E
P/E adj.
E/P
E adj./P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Gilead Sciences profitability

Report period2018 2019 2020 2021 2022 2023
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Gilead Sciences assets
Gilead Sciences cash flows
Gilead Sciences dividends
3.89%

Gilead Sciences shares

TickerNameTypeNominal valueISINPrice
GILD:USGilead Sciences Inc.Common share-US3755581036$72.61
GILD-RM:RMGilead SciencesCommon share$0.001US3755581036RUB 5,216
Gilead Sciences news
08.11.2023
Gilead Sciences' GAAP net income for 9 months of 2023 was $4.196 billion, up 43.1% from $2.933 billion in the prior year. Revenues increased 0.5% to $20 billion from $19.892 billion a year earlier.
08.11.2023
Gilead Sciences Board of Directors announced a quarterly dividend of $0.75 per share. The last day to buy securities to receive the dividend is December 13, 2023. The annual dividend yield may reach 3.8%.
04.08.2023
Gilead Sciences' GAAP net income for 6 months of 2023 was $2.024 billion, up 76.5% from $1.147 billion in the prior year. Revenue increased 0.8% to $12.951 billion from $12.85 billion a year earlier.
28.04.2023
Gilead Sciences Board of Directors announced a quarterly dividend of $0.75 per share. last day to buy securities to receive the dividend is June 13, 2023. Annual dividend yield may reach 3.76%.
General information
Company nameGilead Sciences
Tags#biotechnology, #s&p500 index
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address333 LAKESIDE DR FOSTER CITY CA 94404 6505743000
Mailing address333 LAKESIDE DR FOSTER CITY CA 94404
Websitewww.gilead.com
Information disclosurewww.sec.gov